Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors while in the central nervous process, conolidine modulates alternate molecular targets. A Science Advances analyze identified that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXC